SG
ENVB icon

StoneX Group’s Enveric Biosciences ENVB Stock Holding History

StoneX Group’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9K Buy
+11,814
New +$28.4K ﹤0.01% 1304

Other funds holding ENVB

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

StoneX Group's ENVB Position: Q2 2026 in Review

StoneX Group opened a new position in Enveric Biosciences (ENVB) in Q2 2026: 11,814 shares worth $21.9K. The stake represents ﹤0.01% of the portfolio and ranks #1304 among its holdings.

15 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

  • StoneX Group held 11,814 shares of Enveric Biosciences worth $21.9K as of Q2 2026.
  • Enveric Biosciences was a new StoneX Group position in Q2 2026.
  • Enveric Biosciences made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1304 holding.
  • 15 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.